Fisher Scientific International Inc
Fisher Scientific International — Goldman Sachs Twenty Sixth Annual Global Healthcare Conference 2005
11 slides from Fisher Scientific International's conference presentation, Jun 15, 2005
Slide 1: Goldman Sachs Twenty Sixth Annual Global Healthcare Conference 2005
Goldman Sachs Twenty Sixth Annual Global Healthcare Conference 2005 June 15, 2005
Slide 2: The World Leader in Serving Science
The World Leader in Serving Science Leading supplier to scientific markets One-stop shop for the scientist Addressing complexity in the lab Technology Regulatory Cost pressures Accelerated drug development
Slide 3: Track Record of Accomplishment
Sales Operating Margin Stock Price Equity Market Cap. Track Record of Accomplishment 1991 2005F $0.8 5.2%* $3 $0.2 * Operating margin excludes impact of restructuring and non-recurring items. ** Midpoint of guidance as of June 15, 2005. Operating margin excludes impact of restructuring and non-recur
Slide 4: Serving Large and Growing Markets
Markets Served Global Market: $50 Billion Long Term Growth Rate: 5 - 8% Bipharma 7 Safety 12 Clinical 10 Scientific Research 23 U.S. Clinical Lab $10 billion U.S. Lab Safety and Personal Protection $12 billion Global Scientific Research $23 billion Global Biopharma Production $5 billion No Customer
Slide 5: Providing Value to Customers
Providing Value to Customers Global operations Technical complexity Pressure on costs Regulatory requirements Customer Dynamics Fisher's Value Proposition Global logistics / systems capabilities One-stop shop Value-added services Technical specialists Managing Complexity
Slide 6: Providing Value to Shareholders
Providing Value to Shareholders Operational Efficiencies Expand Product and Service Offering Shareholder Value Leverage Channel Position
Slide 7: Significant Cash Flow Generation
Free Cash Flow* Significant Cash Flow Generation Margin Expansion + = *Midpoint of guidance range of $385-$415 million for 2005 as of June 15, 2005. Free cash flow is defined as cash flow from operating activities less capital expenditures. CAGR = 39% Cash Flow Efficiency
Slide 8: Attractive Earnings Per Share Growth
Attractive Earnings Per Share Growth * Excludes goodwill amortization. ** Range of guidance as of June 15, 2005. Excludes restructuring and non-recurring items. *** Midpoint of guidance range of 13.3 percent to 13.5 percent as of June 15, 2005. Excludes restructuring and non-recurring items. 2000 20
Slide 9: Investment Highlights
Investment Highlights Leader in large and growing markets Proven track record Strong platform for growth Significant cash flow generation
Slide 10: The World Leader in Serving Science
The World Leader in Serving Science
Slide 11: Supplementary Financial Information
(in millions, except per share amounts) Supplementary Financial Information * Operating income for 2003 and 2004 includes the results of Atos Medical AB which was sold on April 5, 2005. * *